Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9, 840

New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment


New Insights Into Implementation of Mesenchymal Stem Cells in Cancer Therapy: Prospects for Anti-angiogenesis Treatment

Mohammad Reza Javan et al. Front Oncol.


Tumor microenvironment interacts with tumor cells, establishing an atmosphere to contribute or suppress the tumor development. Among the cells which play a role in the tumor microenvironment, mesenchymal stem cells (MSCs) have been demonstrated to possess the ability to orchestrate the fate of tumor cells, drawing the attention to the field. MSCs have been considered as cells with double-bladed effects, implicating either tumorigenic or anti-tumor activity. On the other side, the promising potential of MSCs in treating human cancer cells has been observed from the clinical studies. Among the beneficial characteristics of MSCs is the natural tumor-trophic migration ability, providing facility for drug delivery and, therefore, targeted treatment to detach tumor and metastatic cells. Moreover, these cells have been the target of engineering approaches, due to their easily implemented traits, in order to obtain the desired expression of anti-angiogenic, anti-proliferative, and pro-apoptotic properties, according to the tumor type. Tumor angiogenesis is the key characteristic of tumor progression and metastasis. Manipulation of angiogenesis has become an attractive approach for cancer therapy since the introduction of the first angiogenesis inhibitor, namely bevacizumab, for metastatic colorectal cancer therapy. This review tries to conclude the approaches, with focus on anti-angiogenesis approach, in implementing the MSCs to combat against tumor cell progression.

Keywords: angiogenesis; cancer therapy; drug delivery; mesenchymal stem cells; tumor microenvironment.


Figure 1
Figure 1
MSC homing within tumors. Tumor microenvironment modulates an inflammatory condition and releases mediators to recruit MSCs into tumor. These cells become the major constituent of the tumor microenvironment.
Figure 2
Figure 2
Different cytokines and mediators secreted from MSCs during cross-talk with tumor cells that are involved in three major interfaces of homing, growth, and stemness of tumor cells.
Figure 3
Figure 3
Schematic illustration of strategies for tumor therapy with employment of MSC.

Similar articles

See all similar articles

Cited by 3 articles


    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. (2016) 66:7–30. 10.3322/caac.21332 - DOI - PubMed
    1. Sawyers C. Targeted cancer therapy. Nature. (2004) 432:294–7. 10.1038/nature03095 - DOI - PubMed
    1. Corsten MF, Shah K. Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. Lancet Oncol. (2008) 9:376–84. 10.1016/S1470-2045(08)70099-8 - DOI - PubMed
    1. Teo AK, Vallier L. Emerging use of stem cells in regenerative medicine. Biochem J. (2010) 428:11–23. 10.1042/BJ20100102 - DOI - PubMed
    1. Jain RK, Di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogenesis in brain tumours. Nat Rev Neurosci. (2007) 8:610–22. 10.1038/nrn2175 - DOI - PubMed

LinkOut - more resources